# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:RMTI) with a Buy and maintains $9 pri...
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes,...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:RMTI) with a Buy and maintains $9 pri...
The agreement will remain in effect for two years with the option to extend the agreement for an additional one-year period and...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:RMTI) with a Buy and maintains $9 pri...
GUIDANCERockwell Medical updates its 2024 guidance as follows: Updated 2024 Guidance (As of August 8, 2024)Updated 2024 Guidanc...